Dupilumab has been demonstrated to be an effective treatment for patients with moderate-to-severe atopic dermatitis (AD) in clinical trials. However, evidence of real-world experience with dupilumab in a broader population is limited to date.

Use of Dupilumab for 543 Adult Patients with Moderate-To-Severe Atopic Dermatitis: A Multicenter, Retrospective Study / Nettis, E; Ferrucci, S M; Ortoncelli, M; Pellacani, G; Foti, C; Di Leo, E; Patruno, C; Rongioletti, F; Argenziano, G; Macchia, L; Tavecchio, S; Napolitano, M; Ribero, S; Bonzano, L; Romita, P; Di Bona, D; Nisticò, S P; Piras, V; Calabrese, G; Detoraki, C; Carbonara, M; Fabbrocini, G. - In: JOURNAL OF INVESTIGATIONAL ALLERGOLOGY & CLINICAL IMMUNOLOGY. - ISSN 1018-9068. - 32:2(2020), p. 0. [10.18176/jiaci.0641]

Use of Dupilumab for 543 Adult Patients with Moderate-To-Severe Atopic Dermatitis: A Multicenter, Retrospective Study

Patruno, C;Napolitano, M;Piras, V;Fabbrocini, G
2020

Abstract

Dupilumab has been demonstrated to be an effective treatment for patients with moderate-to-severe atopic dermatitis (AD) in clinical trials. However, evidence of real-world experience with dupilumab in a broader population is limited to date.
2020
Use of Dupilumab for 543 Adult Patients with Moderate-To-Severe Atopic Dermatitis: A Multicenter, Retrospective Study / Nettis, E; Ferrucci, S M; Ortoncelli, M; Pellacani, G; Foti, C; Di Leo, E; Patruno, C; Rongioletti, F; Argenziano, G; Macchia, L; Tavecchio, S; Napolitano, M; Ribero, S; Bonzano, L; Romita, P; Di Bona, D; Nisticò, S P; Piras, V; Calabrese, G; Detoraki, C; Carbonara, M; Fabbrocini, G. - In: JOURNAL OF INVESTIGATIONAL ALLERGOLOGY & CLINICAL IMMUNOLOGY. - ISSN 1018-9068. - 32:2(2020), p. 0. [10.18176/jiaci.0641]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11588/849757
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 35
  • ???jsp.display-item.citation.isi??? 31
social impact